{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:22:28Z","timestamp":1794432148710,"version":"4.9.1"},"reference-count":39,"publisher":"American Society of Hematology","issue":"24","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,26]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma; data indicate that blastoid and pleomorphic variants have a poor prognosis. We report characteristics and outcomes of patients with blastoid\/pleomorphic variants of MCL. We retrospectively studied adults with newly diagnosed MCL treated from 2000 to 2015. Primary objectives were to describe progression-free survival (PFS) and overall survival (OS). Secondary objectives included characterization of patient characteristics and treatments. Of the 1029 patients with MCL studied, a total of 207 neoplasms were blastoid or pleomorphic variants. Median follow-up period was 82\u00a0months (range, 0.1-174\u00a0months); median PFS was 38\u00a0months (95% confidence interval [CI], 28-66) and OS was 68\u00a0months (95%\u00a0CI, 45-96). Factors associated with PFS were receipt of consolidative autologous hematopoietic transplantation (auto-HCT; hazard ratio [HR], 0.52; 95%\u00a0CI, 0.31-0.80; P\u00a0&amp;lt; .05), MCL International Prognostic Index (MIPI) intermediate (HR, 2.3; 95%\u00a0CI, 1.2-4.3; P\u00a0&amp;lt; .02) and high (HR, 3.8; 95%\u00a0CI, 2.0-7.4; P\u00a0&amp;lt; .01) scores, and complete response to induction (HR, 0.29 (95%\u00a0CI, 0.17-0.51). Receipt of auto-HCT was not associated with OS (HR, 0.69; 95%\u00a0CI, 0.41-1.16; P\u00a0= .16) but was associated with MIPI intermediate (HR, 5.7; 95%\u00a0CI, 2.5-13.2; P\u00a0&amp;lt; .01) and high (HR, 10.8; 95%\u00a0CI, 4.7-24.9; P\u00a0&amp;lt; .01) scores. We report outcomes in a large cohort of patients with blastoid\/pleomorphic variant MCL. For eligible patients, receipt of auto-HCT after induction was associated with improved PFS but not OS. Higher MIPI score and auto-HCT ineligibility were associated with worse survival.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023010757","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T19:00:59Z","timestamp":1698174059000},"page":"7393-7401","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma"],"prefix":"10.1182","volume":"7","author":[{"given":"James N.","family":"Gerson","sequence":"first","affiliation":[{"name":"1Department of Hematology\/Oncology, Fox Chase Cancer Center, Philadelphia, PA"},{"name":"2Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Handorf","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology, Fox Chase Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4625-3009","authenticated-orcid":false,"given":"Diego","family":"Villa","sequence":"additional","affiliation":[{"name":"3BC Cancer Centre for Lymphoid Cancer, Vancouver, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4727-1425","authenticated-orcid":false,"given":"Alina S.","family":"Gerrie","sequence":"additional","affiliation":[{"name":"3BC Cancer Centre for Lymphoid Cancer, Vancouver, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0306-6756","authenticated-orcid":false,"given":"Parv","family":"Chapani","sequence":"additional","affiliation":[{"name":"3BC Cancer Centre for Lymphoid Cancer, Vancouver, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6857-0523","authenticated-orcid":false,"given":"Shaoying","family":"Li","sequence":"additional","affiliation":[{"name":"4MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6577-8006","authenticated-orcid":false,"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[{"name":"4MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"4MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Medical Oncology, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Churnetski","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Medical Oncology, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Hill","sequence":"additional","affiliation":[{"name":"6Cleveland Clinic Foundation, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6355-3671","authenticated-orcid":false,"given":"Yazeed","family":"Sawalha","sequence":"additional","affiliation":[{"name":"6Cleveland Clinic Foundation, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Hernandez-Ilizaliturri","sequence":"additional","affiliation":[{"name":"7Roswell Park Cancer Institute, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalin","family":"Kothari","sequence":"additional","affiliation":[{"name":"7Roswell Park Cancer Institute, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1015-7434","authenticated-orcid":false,"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[{"name":"8University of Nebraska Cancer Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bast","sequence":"additional","affiliation":[{"name":"8University of Nebraska Cancer Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Fenske","sequence":"additional","affiliation":[{"name":"9Division of Hematology\/Oncology, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapna Narayana","family":"Rao Gari","sequence":"additional","affiliation":[{"name":"9Division of Hematology\/Oncology, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kami J.","family":"Maddocks","sequence":"additional","affiliation":[{"name":"25Division of Hematology, Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0773-1829","authenticated-orcid":false,"given":"David","family":"Bond","sequence":"additional","affiliation":[{"name":"25Division of Hematology, Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[{"name":"10Division of Hematology and Oncology, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4584-9855","authenticated-orcid":false,"given":"Bhaskar","family":"Kolla","sequence":"additional","affiliation":[{"name":"10Division of Hematology and Oncology, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Chavez","sequence":"additional","affiliation":[{"name":"11Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijal","family":"Shah","sequence":"additional","affiliation":[{"name":"11Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6027-3359","authenticated-orcid":false,"given":"Frederick","family":"Lansigan","sequence":"additional","affiliation":[{"name":"12Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Burns","sequence":"additional","affiliation":[{"name":"12Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra M.","family":"Donovan","sequence":"additional","affiliation":[{"name":"12Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6529-9793","authenticated-orcid":false,"given":"Nina","family":"Wagner-Johnston","sequence":"additional","affiliation":[{"name":"13Hematologic Malignancies Division, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8030-1190","authenticated-orcid":false,"given":"Marcus","family":"Messmer","sequence":"additional","affiliation":[{"name":"13Hematologic Malignancies Division, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0537-4207","authenticated-orcid":false,"given":"Amitkumar","family":"Mehta","sequence":"additional","affiliation":[{"name":"14University of Alabama Cancer Center, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Anderson","sequence":"additional","affiliation":[{"name":"14University of Alabama Cancer Center, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishitha","family":"Reddy","sequence":"additional","affiliation":[{"name":"15Vanderbilt Ingram Cancer Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra E.","family":"Kovach","sequence":"additional","affiliation":[{"name":"15Vanderbilt Ingram Cancer Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Landsburg","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Glenn","sequence":"additional","affiliation":[{"name":"16Huntsman Cancer Institute, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Inwards","sequence":"additional","affiliation":[{"name":"17Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Ristow","sequence":"additional","affiliation":[{"name":"17Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-4376","authenticated-orcid":false,"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[{"name":"18Division of Hematology and Oncology, Northwestern University, Evanston, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason B.","family":"Kaplan","sequence":"additional","affiliation":[{"name":"18Division of Hematology and Oncology, Northwestern University, Evanston, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1436-0464","authenticated-orcid":false,"given":"Paolo F.","family":"Caimi","sequence":"additional","affiliation":[{"name":"19Division of Hematology and Oncology, Case Western Reserve University, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Rajguru","sequence":"additional","affiliation":[{"name":"20Division of Hematology, Medical Oncology and Palliative Care, University of Wisconsin, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6900-1824","authenticated-orcid":false,"given":"Andrew","family":"Evens","sequence":"additional","affiliation":[{"name":"21Division of Hematology\/Oncology, Tufts University, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Klein","sequence":"additional","affiliation":[{"name":"21Division of Hematology\/Oncology, Tufts University, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Umyarova","sequence":"additional","affiliation":[{"name":"22Division of Hematology and Oncology, University of Vermont, Burlington, VT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhargavi","family":"Pulluri","sequence":"additional","affiliation":[{"name":"22Division of Hematology and Oncology, University of Vermont, Burlington, VT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4117-2469","authenticated-orcid":false,"given":"Jennifer E.","family":"Amengual","sequence":"additional","affiliation":[{"name":"23Division of Hematology and Oncology, Columbia University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Lue","sequence":"additional","affiliation":[{"name":"23Division of Hematology and Oncology, Columbia University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Diefenbach","sequence":"additional","affiliation":[{"name":"24Division of Hematology and Medical Oncology, New York University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard I.","family":"Fisher","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology, Fox Chase Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology, Fox Chase Cancer Center, Philadelphia, PA"},{"name":"2Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"issue":"11","key":"2023122214470490500_bib1","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.010264","article-title":"SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype","volume":"94","author":"Mozos","year":"2009","journal-title":"Haematologica"},{"issue":"8","key":"2023122214470490500_bib2","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023122214470490500_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/hupa.2002.30221","article-title":"From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades","volume":"33","author":"Swerdlow","year":"2002","journal-title":"Hum Pathol"},{"issue":"26","key":"2023122214470490500_bib4","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-cell lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023122214470490500_bib5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"Perez-Galan","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2023122214470490500_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(00)00255-2","article-title":"Mantle-cell lymphoma","volume":"2","author":"Barista","year":"2001","journal-title":"Lancet Oncol"},{"issue":"9","key":"2023122214470490500_bib7","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3109\/10428194.2013.771400","article-title":"Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop","volume":"54","author":"Williams","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2023122214470490500_bib8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3816\/CLM.2000.n.016","article-title":"Pathologic diagnosis of mantle cell lymphoma","volume":"1","author":"Lai","year":"2000","journal-title":"Clin Lymphoma"},{"issue":"4","key":"2023122214470490500_bib9","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood.V89.4.1421","article-title":"Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones","volume":"89","author":"Ott","year":"1997","journal-title":"Blood"},{"issue":"8","key":"2023122214470490500_bib10","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.24797","article-title":"Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management","volume":"92","author":"Vose","year":"2017","journal-title":"Am J Hematol"},{"issue":"4","key":"2023122214470490500_bib11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bjh.12046","article-title":"Guidelines for the investigation and management of mantle cell lymphoma","volume":"159","author":"McKay","year":"2012","journal-title":"Br J Haematol"},{"issue":"11","key":"2023122214470490500_bib12","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/sj.leu.2402272","article-title":"Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype","volume":"15","author":"Bernard","year":"2001","journal-title":"Leukemia"},{"issue":"26","key":"2023122214470490500_bib13","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1182\/blood-2017-08-737502","article-title":"Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge","volume":"132","author":"Dreyling","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2023122214470490500_bib14","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/17474086.2021.1950529","article-title":"Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma","volume":"14","author":"Goy","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"10","key":"2023122214470490500_bib15","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/S0046-8177(03)00412-X","article-title":"Cytogenetic findings in blastoid mantle cell lymphoma","volume":"34","author":"Khoury","year":"2003","journal-title":"Hum Pathol"},{"issue":"15","key":"2023122214470490500_bib16","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.7314\/APJCP.2015.16.15.6591","article-title":"Ki-67 labeling indices in 'Classic' versus 'Blastoid' mantle cell lymphomas--proposed cutoff values for routine diagnostic workup","volume":"16","author":"Pervez","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"2023122214470490500_bib17","volume-title":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for B-Cell Lymphomas V.2","year":"2022"},{"issue":"4","key":"2023122214470490500_bib18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11899-019-00520-0","article-title":"Mantle cell lymphoma: which patients should we transplant?","volume":"14","author":"Gerson","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"2023122214470490500_bib19","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2023122214470490500_bib20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1200\/JCO.18.00690","article-title":"Survival outcomes of younger patients with mantle cell lymphoma treated in the eituximab era","volume":"37","author":"Gerson","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023122214470490500_bib21","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A\u00a0new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"2023122214470490500_bib22","author":"Klein","year":"2003","edition":"2 ed."},{"issue":"3","key":"2023122214470490500_bib23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00428-015-1840-6","article-title":"Mantle cell lymphoma--a spectrum from indolent to aggressive disease","volume":"468","author":"Sander","year":"2016","journal-title":"Virchows Arch"},{"issue":"6","key":"2023122214470490500_bib24","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3109\/10428194.2015.1094801","article-title":"Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group experience","volume":"57","author":"Bhatt","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2023122214470490500_bib25","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European mantle cell lymphoma network","volume":"34","author":"Hoster","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023122214470490500_bib26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0959-8049(02)00456-2","article-title":"Predictive factors for blastoid transformation in the common variant of mantle cell lymphoma","volume":"39","author":"R\u00e4ty","year":"2003","journal-title":"Eur J Cancer"},{"issue":"3","key":"2023122214470490500_bib27","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.21.02698","article-title":"Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts","volume":"41","author":"Martin","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023122214470490500_bib28","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL elderly trial","volume":"38","author":"Kluin-Nelemans","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"2023122214470490500_bib29","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023122214470490500_bib30","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule","year":"2019","journal-title":"Haematologica"},{"issue":"10121","key":"2023122214470490500_bib31","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"21","key":"2023122214470490500_bib32","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2023122214470490500_bib33","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam","year":"2021","journal-title":"Blood Adv"},{"issue":"26","key":"2023122214470490500_bib34","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"2023122214470490500_bib35","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2023122214470490500_bib36","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2021-151831","article-title":"Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)","volume":"138","author":"Kumar","year":"2021","journal-title":"Blood (2021)"},{"issue":"10277","key":"2023122214470490500_bib37","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"2023122214470490500_bib38","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"2023122214470490500_bib39","author":"Dreyling","year":"15  2022"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/24\/7393\/2177829\/blooda_adv-2023-010757-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/24\/7393\/2177829\/blooda_adv-2023-010757-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T14:47:33Z","timestamp":1703256453000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/24\/7393\/498405\/Outcomes-of-patients-with-blastoid-and-pleomorphic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,13]]},"references-count":39,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2023,12,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010757","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,13]]}}}